A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer

BJU Int. 2009 Mar:103 Suppl 2:7-13. doi: 10.1111/j.1464-410X.2009.08383.x.

Author

Peter Schlegel¹

Affiliation

¹ Department of Urology, Weill Cornell Medical College, New York, NY 10021, USA. pnschleg@med.cornell.edu

PMID: 19228147
DOI: 10.1111/j.1464-410X.2009.08383.x

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Absorption
Antineoplastic Agents, Hormonal / administration & dosage*
Antineoplastic Agents, Hormonal / pharmacokinetics
Biological Availability
Delayed-Action Preparations
Drug Administration Schedule
Drug Implants
Follicle Stimulating Hormone / antagonists & inhibitors
Gonadotropin-Releasing Hormone / administration & dosage
Gonadotropin-Releasing Hormone / analogs & derivatives*
Gonadotropin-Releasing Hormone / pharmacokinetics
Humans
Luteinizing Hormone / antagonists & inhibitors
Male
Prostatic Neoplasms / drug therapy*
Testosterone / antagonists & inhibitors

Substances

Antineoplastic Agents, Hormonal
Delayed-Action Preparations
Drug Implants
Gonadotropin-Releasing Hormone
Testosterone
Luteinizing Hormone
Follicle Stimulating Hormone
histrelin